Cosmo Pharmaceuticals Files Marketing Authorization Application for Methylene Blue MX 200 mg Tablets with European Medicines Agency
Cosmo Pharmaceuticals N.V. announced the filing of a Marketing Authorization Application for Methylene Blue MMX 200 mg tablets with the European Medicines Agency (EMA). Methylene Blue MMX is intended as an aid for the visualization and the detection of lesions in subjects undergoing colonoscopy.